PYC THERAPEUTICS LIMITED - Announcements

6.43%

$1.33

Market Cap $772.8M

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

BPH Energy (ASX:BPH) continues court battle while eastern states energy crisis worsens

Announcements

Filter Results

All Price Sensitive Only

PYC	ICR Conference Presentation		14/01/21	1.51MB	Share
PYC	PYC to Present at ICR Westwicke Conference		06/01/21	143.48KB	Share
PYC	Appendix 3G		16/12/20	329.3KB	Share
PYC	Initial Director's Interest Notice		16/12/20	250.53KB	Share
PYC	Visual Evidence of Lead Drugs Efficacy	PRICE SENSITIVE	16/12/20	302.88KB	Share
PYC	Letter to Shareholders from the US CEO		14/12/20	91.43KB	Share
PYC	Appointment of Chief Executive Officer in the United States		10/12/20	110.93KB	Share
PYC	PYC to Present at the Evercore ISI Conference		25/11/20	88.57KB	Share
PYC	Change in substantial holding		18/11/20	117.45KB	Share
PYC	Retail Entitlement Offer Share Issue and Appendix 2A		18/11/20	383.77KB	Share
PYC	Completion of Retail Entitlement Offer		13/11/20	119.9KB	Share
PYC	Final Director's Interest Notice		10/11/20	187.23KB	Share
PYC	New Constitution		06/11/20	2.45MB	Share
PYC	Results of Annual General Meeting		06/11/20	102.29KB	Share
PYC	AGM Chairman's Address and CEO Presentation		06/11/20	610.16KB	Share
PYC	Grants Awarded to Support Clinical Progression of Lead Drug		29/10/20	225.31KB	Share
PYC	Notice under Section 708(A)		28/10/20	26.18KB	Share
PYC	Change of Director's Interest Notice x 2		28/10/20	461.1KB	Share
PYC	Change in substantial holding		28/10/20	97.35KB	Share
PYC	Appendix 2A		27/10/20	273.59KB	Share
PYC	Review of Activities and Appendix 4C	PRICE SENSITIVE	26/10/20	230.99KB	Share
PYC	Dispatch of Notice to Ineligible Retail Shareholders		26/10/20	119.42KB	Share
PYC	Dispatch of Retail Offer Document		26/10/20	2.94MB	Share
PYC	FDA Response to Orphan drug Designation Request		23/10/20	109.53KB	Share
PYC	Successful Institutional Entitlement Offer and Placement	PRICE SENSITIVE	22/10/20	287.4KB	Share
PYC	PYC Business and Equity Raising Presentation	PRICE SENSITIVE	20/10/20	1.52MB	Share
PYC	PYC Equity Raising to Raise up to $55 Million	PRICE SENSITIVE	20/10/20	396.91KB	Share
PYC	Proposed issue of Securities - PYC		20/10/20	38.06KB	Share
PYC	Cleansing Notice Under Section 708AA		20/10/20	30.9KB	Share
PYC	Trading Halt	PRICE SENSITIVE	16/10/20	295.26KB	Share
PYC	New Drug for Substantial Unmet Need Added to Pipeline	PRICE SENSITIVE	12/10/20	228.7KB	Share
PYC	Investor Call 15th Oct 2020 12pm AEDT 9am AWST		09/10/20	86.26KB	Share
PYC	Cancellation of Unlisted Options		09/10/20	82.04KB	Share
PYC	Notice of Directors intention not to seek re election at AGM		09/10/20	80.04KB	Share
PYC	Technical Presentation - October 2020		09/10/20	4.25MB	Share
PYC	PYC's Lead Drug Effective in Patient Derived Models Tested	PRICE SENSITIVE	07/10/20	147.03KB	Share
PYC	Notice of Annual General Meeting/Proxy Form		05/10/20	806.38KB	Share
PYC	Corporate Governance Statement and Appendix 4G		05/10/20	420.45KB	Share
PYC	Annual Report to shareholders		05/10/20	3.72MB	Share
PYC	Second Potential Blockbuster Drug Added to PYC's Pipeline	PRICE SENSITIVE	05/10/20	195.93KB	Share
PYC	Annual Financial Statements June 2020		14/09/20	1.11MB	Share
PYC	Creation of Novel Gene Therapy Delivery Technology	PRICE SENSITIVE	08/09/20	256.32KB	Share
PYC	Appendix 4E Preliminary Final Report	PRICE SENSITIVE	31/08/20	343.8KB	Share
PYC	Appointment of world-renowned Chief Scientific Officer		19/08/20	92.03KB	Share
PYC	Executive re-structure across global operations	PRICE SENSITIVE	19/08/20	82.17KB	Share
PYC	Shareholder Update August 2020		14/08/20	2.42MB	Share
PYC	Shareholder Update - Forward View 2020 Milestones	PRICE SENSITIVE	05/08/20	144.91KB	Share
PYC	Investor Call - 8am AWST - Wednesday 12 August 2020		03/08/20	104.64KB	Share
PYC	June 2020 Quarterly Activity Report and Cashflow	PRICE SENSITIVE	30/07/20	196.06KB	Share
PYC	Successful Dose Response & Toxicity Studies in Lead Program	PRICE SENSITIVE	22/07/20	181.82KB	Share
PYC	Appendix 2A		09/07/20	318.4KB	Share
PYC	Appendix 3G		30/06/20	413.67KB	Share
PYC	Investor Presentation June 2020		22/06/20	2.74MB	Share
PYC	Change of Director's Interest Notice x 2		16/06/20	421.41KB	Share
PYC	Change in substantial holding		16/06/20	36.93KB	Share
PYC	Change in substantial holding		16/06/20	120.83KB	Share
PYC	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
PYC	PYC Recruits High Profile Chief Medical Officer to US Ops		09/06/20	91.55KB	Share
PYC	Appendix 3G		04/06/20	269.93KB	Share
PYC	World Class Results - Lions Eye Institute News Release		25/05/20	124.9KB	Share
PYC	March 2020 Quarterly Activities and Cash Flow Report	PRICE SENSITIVE	29/04/20	192.29KB	Share
PYC	Efficacy and Toxicity Studies Presentation		15/04/20	2.25MB	Share
PYC	Successful Toxicity Results Confirm Safety Advantage		08/04/20	240.65KB	Share
PYC	Investor call 12.00pm AEST Wednesday 1 April 2020		01/04/20	81.91KB	Share
PYC	Successful Efficacy Result on Path to First in Human Studies	PRICE SENSITIVE	01/04/20	564.48KB	Share
PYC	Investor Call 9.00am AWST Wed 1 April 2020		30/03/20	82.49KB	Share
PYC	Trading Halt	PRICE SENSITIVE	30/03/20	301.8KB	Share
PYC	Becoming a substantial holder		20/03/20	107.17KB	Share
PYC	Appendix 3G		18/03/20	342.37KB	Share
PYC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/20	580.54KB	Share
PYC	Investor Presentation - February 2020	PRICE SENSITIVE	24/02/20	2.07MB	Share
PYC	Appendix 3G		19/02/20	271.66KB	Share
PYC	NHMRC grant for identifying new antisense drugs		17/02/20	107.93KB	Share
PYC	Initial Director's Interest Notice		12/02/20	91.18KB	Share
PYC	CEO Appointment and Establishment of US Office	PRICE SENSITIVE	12/02/20	125.02KB	Share
PYC	Investor Call 27 February 2020		05/02/20	82.64KB	Share
PYC	Expansion Of Drug Development Pipeline	PRICE SENSITIVE	03/02/20	116.07KB	Share
PYC	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	56.42KB	Share
PYC	Change of Share Registry		20/01/20	234.34KB	Share
PYC	Quarterly Shareholder Update	PRICE SENSITIVE	06/01/20	90.41KB	Share
PYC	Drug Delivery Greater Than 100% More Effective - Amended		05/12/19	140.8KB	Share
PYC	Change in substantial holding		02/12/19	174.26KB	Share
PYC	Change in substantial holding		02/12/19	37.28KB	Share
PYC	Change in Director's Interest Notices x 2		02/12/19	546.8KB	Share
PYC	Ceasing to be a substantial holder		02/12/19	83.19KB	Share
PYC	Drug Delivery Greater Than 100% More Effective In Animals	PRICE SENSITIVE	02/12/19	213.35KB	Share
PYC	Appendix 3B		28/11/19	170.5KB	Share
PYC	Change in substantial holding		27/11/19	406.67KB	Share
PYC	Results of 2019 Annual General Meeting		21/11/19	82.81KB	Share
PYC	2019 AGM Chairman's Address		21/11/19	94.32KB	Share
PYC	2019 AGM Presentation		21/11/19	886.57KB	Share
PYC	Completion of Retail Entitlement Offer		21/11/19	83.44KB	Share
PYC	Conclusion of Genentech Antimicrobial Collaboration	PRICE SENSITIVE	15/11/19	237.67KB	Share
PYC	PYC Increases Shareholding in Vision Pharma	PRICE SENSITIVE	14/11/19	78.29KB	Share
PYC	Change of Director's Interest Notice		12/11/19	247.42KB	Share
PYC	Change in substantial holding		12/11/19	87.29KB	Share
PYC	Change in substantial holding		11/11/19	37.23KB	Share
PYC	Appendix 3B - Institutional Offer		08/11/19	129.12KB	Share
PYC	Letter - Ineligible Shareholders		07/11/19	31.59KB	Share
PYC	Despatch of Retail Offer Document		07/11/19	83.91KB	Share

PYC ICR Conference Presentation
14/01/21		1.51MB	Share
PYC PYC to Present at ICR Westwicke Conference
06/01/21		143.48KB	Share
PYC Appendix 3G
16/12/20		329.3KB	Share
PYC Initial Director's Interest Notice
16/12/20		250.53KB	Share
PYC Visual Evidence of Lead Drugs Efficacy
16/12/20	PRICE SENSITIVE	302.88KB	Share
PYC Letter to Shareholders from the US CEO
14/12/20		91.43KB	Share
PYC Appointment of Chief Executive Officer in the United States
10/12/20		110.93KB	Share
PYC PYC to Present at the Evercore ISI Conference
25/11/20		88.57KB	Share
PYC Change in substantial holding
18/11/20		117.45KB	Share
PYC Retail Entitlement Offer Share Issue and Appendix 2A
18/11/20		383.77KB	Share
PYC Completion of Retail Entitlement Offer
13/11/20		119.9KB	Share
PYC Final Director's Interest Notice
10/11/20		187.23KB	Share
PYC New Constitution
06/11/20		2.45MB	Share
PYC Results of Annual General Meeting
06/11/20		102.29KB	Share
PYC AGM Chairman's Address and CEO Presentation
06/11/20		610.16KB	Share
PYC Grants Awarded to Support Clinical Progression of Lead Drug
29/10/20		225.31KB	Share
PYC Notice under Section 708(A)
28/10/20		26.18KB	Share
PYC Change of Director's Interest Notice x 2
28/10/20		461.1KB	Share
PYC Change in substantial holding
28/10/20		97.35KB	Share
PYC Appendix 2A
27/10/20		273.59KB	Share
PYC Review of Activities and Appendix 4C
26/10/20	PRICE SENSITIVE	230.99KB	Share
PYC Dispatch of Notice to Ineligible Retail Shareholders
26/10/20		119.42KB	Share
PYC Dispatch of Retail Offer Document
26/10/20		2.94MB	Share
PYC FDA Response to Orphan drug Designation Request
23/10/20		109.53KB	Share
PYC Successful Institutional Entitlement Offer and Placement
22/10/20	PRICE SENSITIVE	287.4KB	Share
PYC PYC Business and Equity Raising Presentation
20/10/20	PRICE SENSITIVE	1.52MB	Share
PYC PYC Equity Raising to Raise up to $55 Million
20/10/20	PRICE SENSITIVE	396.91KB	Share
PYC Proposed issue of Securities - PYC
20/10/20		38.06KB	Share
PYC Cleansing Notice Under Section 708AA
20/10/20		30.9KB	Share
PYC Trading Halt
16/10/20	PRICE SENSITIVE	295.26KB	Share
PYC New Drug for Substantial Unmet Need Added to Pipeline
12/10/20	PRICE SENSITIVE	228.7KB	Share
PYC Investor Call 15th Oct 2020 12pm AEDT 9am AWST
09/10/20		86.26KB	Share
PYC Cancellation of Unlisted Options
09/10/20		82.04KB	Share
PYC Notice of Directors intention not to seek re election at AGM
09/10/20		80.04KB	Share
PYC Technical Presentation - October 2020
09/10/20		4.25MB	Share
PYC PYC's Lead Drug Effective in Patient Derived Models Tested
07/10/20	PRICE SENSITIVE	147.03KB	Share
PYC Notice of Annual General Meeting/Proxy Form
05/10/20		806.38KB	Share
PYC Corporate Governance Statement and Appendix 4G
05/10/20		420.45KB	Share
PYC Annual Report to shareholders
05/10/20		3.72MB	Share
PYC Second Potential Blockbuster Drug Added to PYC's Pipeline
05/10/20	PRICE SENSITIVE	195.93KB	Share
PYC Annual Financial Statements June 2020
14/09/20		1.11MB	Share
PYC Creation of Novel Gene Therapy Delivery Technology
08/09/20	PRICE SENSITIVE	256.32KB	Share
PYC Appendix 4E Preliminary Final Report
31/08/20	PRICE SENSITIVE	343.8KB	Share
PYC Appointment of world-renowned Chief Scientific Officer
19/08/20		92.03KB	Share
PYC Executive re-structure across global operations
19/08/20	PRICE SENSITIVE	82.17KB	Share
PYC Shareholder Update August 2020
14/08/20		2.42MB	Share
PYC Shareholder Update - Forward View 2020 Milestones
05/08/20	PRICE SENSITIVE	144.91KB	Share
PYC Investor Call - 8am AWST - Wednesday 12 August 2020
03/08/20		104.64KB	Share
PYC June 2020 Quarterly Activity Report and Cashflow
30/07/20	PRICE SENSITIVE	196.06KB	Share
PYC Successful Dose Response & Toxicity Studies in Lead Program
22/07/20	PRICE SENSITIVE	181.82KB	Share
PYC Appendix 2A
09/07/20		318.4KB	Share
PYC Appendix 3G
30/06/20		413.67KB	Share
PYC Investor Presentation June 2020
22/06/20		2.74MB	Share
PYC Change of Director's Interest Notice x 2
16/06/20		421.41KB	Share
PYC Change in substantial holding
16/06/20		36.93KB	Share
PYC Change in substantial holding
16/06/20		120.83KB	Share
PYC S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
PYC PYC Recruits High Profile Chief Medical Officer to US Ops
09/06/20		91.55KB	Share
PYC Appendix 3G
04/06/20		269.93KB	Share
PYC World Class Results - Lions Eye Institute News Release
25/05/20		124.9KB	Share
PYC March 2020 Quarterly Activities and Cash Flow Report
29/04/20	PRICE SENSITIVE	192.29KB	Share
PYC Efficacy and Toxicity Studies Presentation
15/04/20		2.25MB	Share
PYC Successful Toxicity Results Confirm Safety Advantage
08/04/20		240.65KB	Share
PYC Investor call 12.00pm AEST Wednesday 1 April 2020
01/04/20		81.91KB	Share
PYC Successful Efficacy Result on Path to First in Human Studies
01/04/20	PRICE SENSITIVE	564.48KB	Share
PYC Investor Call 9.00am AWST Wed 1 April 2020
30/03/20		82.49KB	Share
PYC Trading Halt
30/03/20	PRICE SENSITIVE	301.8KB	Share
PYC Becoming a substantial holder
20/03/20		107.17KB	Share
PYC Appendix 3G
18/03/20		342.37KB	Share
PYC Half Yearly Report and Accounts
28/02/20	PRICE SENSITIVE	580.54KB	Share
PYC Investor Presentation - February 2020
24/02/20	PRICE SENSITIVE	2.07MB	Share
PYC Appendix 3G
19/02/20		271.66KB	Share
PYC NHMRC grant for identifying new antisense drugs
17/02/20		107.93KB	Share
PYC Initial Director's Interest Notice
12/02/20		91.18KB	Share
PYC CEO Appointment and Establishment of US Office
12/02/20	PRICE SENSITIVE	125.02KB	Share
PYC Investor Call 27 February 2020
05/02/20		82.64KB	Share
PYC Expansion Of Drug Development Pipeline
03/02/20	PRICE SENSITIVE	116.07KB	Share
PYC Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	56.42KB	Share
PYC Change of Share Registry
20/01/20		234.34KB	Share
PYC Quarterly Shareholder Update
06/01/20	PRICE SENSITIVE	90.41KB	Share
PYC Drug Delivery Greater Than 100% More Effective - Amended
05/12/19		140.8KB	Share
PYC Change in substantial holding
02/12/19		174.26KB	Share
PYC Change in substantial holding
02/12/19		37.28KB	Share
PYC Change in Director's Interest Notices x 2
02/12/19		546.8KB	Share
PYC Ceasing to be a substantial holder
02/12/19		83.19KB	Share
PYC Drug Delivery Greater Than 100% More Effective In Animals
02/12/19	PRICE SENSITIVE	213.35KB	Share
PYC Appendix 3B
28/11/19		170.5KB	Share
PYC Change in substantial holding
27/11/19		406.67KB	Share
PYC Results of 2019 Annual General Meeting
21/11/19		82.81KB	Share
PYC 2019 AGM Chairman's Address
21/11/19		94.32KB	Share
PYC 2019 AGM Presentation
21/11/19		886.57KB	Share
PYC Completion of Retail Entitlement Offer
21/11/19		83.44KB	Share
PYC Conclusion of Genentech Antimicrobial Collaboration
15/11/19	PRICE SENSITIVE	237.67KB	Share
PYC PYC Increases Shareholding in Vision Pharma
14/11/19	PRICE SENSITIVE	78.29KB	Share
PYC Change of Director's Interest Notice
12/11/19		247.42KB	Share
PYC Change in substantial holding
12/11/19		87.29KB	Share
PYC Change in substantial holding
11/11/19		37.23KB	Share
PYC Appendix 3B - Institutional Offer
08/11/19		129.12KB	Share
PYC Letter - Ineligible Shareholders
07/11/19		31.59KB	Share
PYC Despatch of Retail Offer Document
07/11/19		83.91KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.33		Change 0.080(6.43%)		Mkt cap ! $772.8M

Open	High	Low	Value	Volume
$1.27	$1.35	$1.21	$763.8K	595.4K

Buyers (Bids)

No.	Vol.	Price($)
2	97719	$1.30

Sellers (Offers)

Price($)	Vol.	No.
$1.33	6599	1

View Market Depth

No.	Vol.	Price($)
2	97719	1.300
1	4027	1.240
1	40000	1.220
1	1000	1.200
2	10830	1.190

Price($)	Vol.	No.
1.325	6599	1
1.395	7168	1
1.400	18450	1
1.420	26097	2
1.430	13000	1

Last trade - 16.10pm 08/08/2025 (20 minute delay)

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories